What is CLYM's current stock price?

CLYM (Climb Bio, Inc.) is currently trading at $11.00 with a market cap of $750.0M.

What sector is Climb Bio, Inc. in?

Climb Bio, Inc. (CLYM) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is CLYM a good stock to buy?

Analysts have a Buy consensus on CLYM with a price target of $20.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

CLYM Climb Bio, Inc.

Healthcare

$11.00+0.82%ClosedMarket Cap: $750.0M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

5.07

P/S

0.00

EV/EBITDA

-13.27

DCF Value

$0.49

FCF Yield

-7.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-31.5%

ROA

-34.6%

ROIC

-40.4%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-13.7M	$—
Q4 null	$0.00	$-17.5M	$—
FY null	$0.00	$-59.9M	$—
Q3 null	$0.00	$-12.9M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$20.00

Target (Median)

$20.00

Target Range

$17.00 - $25.00

1 Strong Buy13 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-05-12

WedbushOutperform

2026-05-08

BTIGBuy

2026-05-06

OppenheimerOutperform

2026-04-21

HC Wainwright & Co.Buy

2026-03-10

Trading Activity

Insider Trades

View All

RA CAPITAL MANAGEMENT, L.P.director, 10 percent owner:

SellWed Apr 29

Thomas Stephen Basildirector

SellFri Feb 27

Thomas Stephen Basildirector

SellFri Feb 27

Thomas Stephen Basildirector

SellTue Feb 17

Thomas Stephen Basildirector

SellTue Feb 17

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.05

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Peers

INO